Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 56 results for tuberculosis"

  1. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued Reference number: GID-DT9

    Diagnostics guidance
    Discontinued

  2. Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

    This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.

    NICE guideline
    Published
    25 January 2017
    View recommendations

    Sections for NG63

  3. Drug misuse in over 16s: psychosocial interventions (CG51)

    This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

    Clinical guideline
    Published
    25 July 2007
    View recommendations

    Sections for CG51

  4. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  5. High-risk groups:- What interventions to prevent infection and reduce antimicrobial resistance are effective for groups of people at high risk of infection? This includes people who:- have suppressed immune systems (for example, because of HIV, an inherited condition or treatment they may be having for conditions such as cancer or an organ transplant)- have a chronic disease- live in crowded conditions (see Shelter's definition)- are homeless- have been in prison- have migrated from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa).

    from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa)....

    Research recommendation
    Published
    17 February 2017

  6. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

    Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    22 June 2011
    View recommendations

    Sections for TA225

  7. Infliximab for treating moderate to severe plaque psoriasis (TA134)

    Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA134

  8. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  9. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  10. What effects does isolation have on the quality of life of people being treated for TB?

    reported. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other

    Research recommendation
    Published
    8 November 2019

  11. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 December 2008
    View recommendations

    Sections for TA163

  12. Adalimumab for treating moderate to severe plaque psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.

    Technology appraisal guidance
    Published
    25 June 2008
    View recommendations

    Sections for TA146

  13. For isoniazid-resistant TB, what is the most effective regimen for reducing mortality andmorbidity?

    events. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other

    Research recommendation
    Published
    8 November 2019

  14. Apart from culture, what other diagnostic tests or combinations of tests are effective inestablishing an accurate diagnosis of active respiratory TB in children and young people withsuspected active TB?

    response. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other

    Research recommendation
    Published
    8 November 2019

  15. For people with active, drug susceptible TB who experience treatment interruptions because of adverse events, particularly hepatotoxicity, what approach to re-establishing treatment is mosteffective in reducing mortality and morbidity?

    useful. Source guidance details Comes from guidance Tuberculosis Number NG33 Date issued January 2016 Other

    Research recommendation
    Published
    8 November 2019